Department of Medicine
Javeed Shah is an infectious diseases physician who has a specific interest in the ongoing care of individuals with HIV. Additionally, he has an interest in caring for individuals with chronic infections like tuberculosis and hepatitis C. His education and training include a B.A. from the University of Chicago, an M.D. from the University of Chicago Pritzker School of Medicine, a residency at the University of Washington, chief residency at Harborview Medical Center, and infectious diseases fellowship at the University of Washington.
Dr. Shah's research interests involve better understanding the immune response to infections like tuberculosis and leprosy, and how vaccines and therapeutics may be better designed to reduce the burden of disease to these infections. He has published over 10 peer-reviewed articles in his time as a researcher. He is a member of the American Medical Association and the Infectious Diseases Society of America.
Tuberculosis, vaccines, dendritic cells, innate immunity, genetics, and immune regulation.
The Shah laboratory studies the immunology of intracellular infections. We are interested in the molecular mechanisms that mediate tuberculosis and chronic lung disease and developing new translational therapies directed against them. Our group uses a combination of hypothesis-free genetic and transcriptional approaches, favoring the concept that insights generated in this manner are likely to have relevance to human disease, accompanied by hypothesis-driven validation studies to improve the rigor and reproducibility of the work conducted in our lab. Currently, our major focus is on the TOLLIP gene, as we found that genetic vaariation within this gene is associated with tuberculosis, other lung and intracellular infections, and inflammatory diseases. We seek to fully explain how common variation in this gene potentiates tuberculosis risk independently of all historic risk factors for this infection. Our group pursues the goal of true ‘bench-to-bedside’ translation, and includes studies in basic genetics, molecular biology, and work with mouse models. Ultimately, we seek to develop a platform of new therapies and vaccines directed against tuberculosis, which is now the leading infectious disease killer worldwide.
HIV; tuberculosis; hepatitis C; general internal medicine.